Expression Of LYVE-1, CD31 In Ovarian Epithelial Neoplasms And The Correlation With Neoplasm Metastasis

Objective The recent discovery of a new HA receptor, LYVE-1(lymphatic vessel endothelial HAreceptor), is expressed predominantly in lymphatic vessels. It is a reliable marker of lymphaticendothelial cells, and used extensively in investigation of tumor lymphangiogenesis. To detect theexpression of specific marker of lymphatic endothelial cells LYVE-1 and epithelial marker CD31 inthe tissues of ovarian epithelial neoplasms, and to explore their roles in the neoplasm metastasis.Methods The expression of LYVE-1 and CD31 in ovarian epithelial neoplasms were detected byEnVision immunohistochemical method, LYVE-1 positive microlymphatic count and CD31microvessel density were assessed.Results 1. In ovarian epithelial carcinomas, MLC(7.97±1.19) were significantly higher thanthose in bordline ovarian neoplasms (MLC, 6.25±1.03) and benign tumors (MLC, 5.33±0.97) (P＜0.01).2. In ovarian epithelial carcinomas, MVD(90.67±16.22) were significantly higher than those inbordline ovarian neoplasms (MVD, 40.87±3.09) and benign tumors (MVD, 33.07±4.62) (P＜0.01).3. MLC (8.60±0.82) in ovarian epithelial carcinomas were higher in the cases of histologic gradeG₃ than those of G₁-G₂ (MLC, 6.70±0.67)(P＜0.05). There are also great differences between theclinical stageâ…¢-â…£(MLC, 8.45±0.96)andâ… -â…¡(MLC, 6.62±0.52) (P＜0.01). MLC(8.93±0.61) in ovarian epithelial carcinomas with lymphatic metastasis were higher than those withoutlymphatic metastasis(MLC, 7.12±0.88)(P＜0.01). There are no significant differences betweenMLC and histologic type in ovarian epithelial carcinomas (P＞0.05).4. MVD(98.60±13.50) in ovarian epithelial carcinomas were higher in the cases of histologicgrade G₃ than those of G₁-G₂ (MVD, 74.80±6.56)(MVD, P＜0.01).There are also great differencesbetween the clinical stageâ…¢-â…£(MVD, 96.45±14.68)andâ… -â…¡(MVD, 74.75±6.94) (P＜0.01).MVD(103.14±13.57) in ovarian epithelial carcinomas with lymphatic metastasis were higher than those without lymphatic metastasis(MVD, 79.75±8.74)(P＜0.01). There are no significantdifferences between MVD and histologic type in ovarian epithelial carcinomas (P＞0.05).5. Pearson analysis showed correlations between LYVE-land CD31(r=0. 801, P＜0.01).Conclusions 1. MLC in ovarian epithelial carcinomas were significantly higher than those inbordline ovarian neoplasms and benign tumors. The expression of LYVE-1 in ovarian epithelialcarcinomas not only predict peritumoral lymphangiogenesis but also play an important role in theneoplasm metastasis. It predict that tumours can induce lymphangiogenesis.2. MVD in ovarian epithelial carcinomas were significantly higher than those in bordline ovarianneoplasms and benign tumors. The expression of CD31 in ovarian epithelial carcinomas not onlypredict angiogenesis but also play an important role in the neoplasm metastasis.3. High expression of LYVE-1 and CD31 were related to clinical stage and pathological grade inovarian epithelial carcinomas. The results show that high expression LYVE-1 and CD31 may relatewith the development of ovarian epithelial carcinomas predict poor prognosis.4. The expression of LYVE-1 and CD31 in ovarian epithelial carcinomas not only predict peritumorallymphangiogenesis and angiogenesis but also play an important role in the neoplasm metastasis. Thefunctional role of LYVE-1 in lymphatic vessels and its application as a marker to study tumorlymphangiogenesis are important areas of investigation.